The VNTR in complex disorders: The forgotten polymorphisms? A functional way forward?

Genomics

Volumn 101, Issue 5, 2013, Pages 273-281

  Brookes, K J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Functional; Gene expression; Polymorphism; Review; Variable Number Tandem Repeat

Indexed keywords

COPY NUMBER VARIATION; DNA REPLICATION; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE REPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC CODE; GENETIC DISORDER; GENETIC TRAIT; GENETIC VARIABILITY; HERITABILITY; HUMAN; INHERITANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; GENETIC ASSOCIATION STUDIES; GENETIC DISEASES, INBORN; HUMANS; MINISATELLITE REPEATS; OPEN READING FRAMES; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 84876415469     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2013.03.003     Document Type: Review

References (136)

1. Achilleos A., Trainor P.A. Neural crest stem cells: discovery, properties and potential for therapy. Cell Res. 2012, 22(2):288-304.
2. Ahmed S., Bennett S.T., et al. INS VNTR allelic variation and dynamic insulin secretion in healthy adult non-diabetic Caucasian subjects. Diabet. Med. 1999, 16(11):910-917.
3. Asghari V., Sanyal S., et al. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J. Neurochem. 1995, 65(3):1157-1165.
4. Asghari V., Schoots O., et al. Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol. Pharmacol. 1994, 46(2):364-373.
5. Aslund C., Nordquist N., et al. Maltreatment, MAOA, and delinquency: sex differences in gene-environment interaction in a large population-based cohort of adolescents. Behav. Genet. 2011, 41(2):262-272.
6. Awata T., Kurihara S., et al. Evidence for association between the class I subset of the insulin gene minisatellite (IDDM2 locus) and IDDM in the Japanese population. Diabetes 1997, 46(10):1637-1642.
7. Bahn S., Augood S.J., et al. Gene expression profiling in the post-mortem human brain-no cause for dismay. J. Chem. Neuroanat. 2001, 22(1-2):79-94.
8. Barton A.J., Pearson R.C., et al. Pre- and postmortem influences on brain RNA. J. Neurochem. 1993, 61(1):1-11.
9. Bazaes R.A., Petry C.J., et al. Insulin gene VNTR genotype is associated with insulin sensitivity and secretion in infancy. Clin. Endocrinol. (Oxf.) 2003, 59(5):599-603.
10. Bell G.I., Horita S., et al. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984, 33(2):176-183.
11. Bell G.I., Karam J.H., et al. Properties of a polymorphic DNA segment in the 5' flanking region of the human insulin gene. Prog. Clin. Biol. Res. 1982, 103(Pt A):57-65.
12. Bennett S.T., Lucassen A.M., et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat. Genet. 1995, 9(3):284-292.
13. Bennett S.T., Wilson A.J., et al. IDDM2-VNTR-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus. J. Autoimmun. 1996, 9(3):415-421.
14. Bornman D.M., Hester M.E., et al. Short-read, high-throughput sequencing technology for STR genotyping. Biotechniques 2012, 1-6.
15. Bouatia-Naji N., De Graeve F., et al. INS VNTR is not associated with childhood obesity in 1,023 families: a family-based study. Obesity (Silver Spring) 2008, 16(6):1471-1475.
16. Brookes K.J., Neale B.M., et al. Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B(8):1070-1078.
17. Brookes K.J., Xu X., et al. No evidence for the association of DRD4 with ADHD in a Taiwanese population within-family study. BMC Med. Genet. 2005, 6:31.
18. Cacabelos R., Martinez R., et al. Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. Int. J. Alzheimers Dis. 2012, 2012:518901.
19. Cai C.Q., Zhang T., et al. Both polymorphic variable number of tandem repeats and autoimmune regulator modulate differential expression of insulin in human thymic epithelial cells. Diabetes 2011, 60(1):336-344.
20. Cantor R.M., Lange K., et al. Prioritizing GWAS results: a review of statistical methods and recommendations for their application. Am. J. Hum. Genet. 2010, 86(1):6-22.
21. Carroll L.S., Owen M.J. Genetic overlap between autism, schizophrenia and bipolar disorder. Genome Med. 2009, 1(10):102.
22. Caspi A., McClay J., et al. Role of genotype in the cycle of violence in maltreated children. Science 2002, 297(5582):851-854.
23. Caspi A., Sugden K., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301(5631):386-389.
24. Chio C.L., Drong R.F., et al. D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. J. Biol. Chem. 1994, 269(16):11813-11819.
25. Cirulli E.T., Goldstein D.B. In vitro assays fail to predict in vivo effects of regulatory polymorphisms. Hum. Mol. Genet. 2007, 16(16):1931-1939.
26. Cook E.H., Stein M.A., et al. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 1995, 56(4):993-998.
27. Deckert J., Catalano M., et al. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum. Mol. Genet. 1999, 8(4):621-624.
28. Denney R.M., Koch H., et al. Association between monoamine oxidase A activity in human male skin fibroblasts and genotype of the MAOA promoter-associated variable number tandem repeat. Hum. Genet. 1999, 105(6):542-551.
29. Ding Y.C., Chi H.C., et al. Evidence of positive selection acting at the human dopamine receptor D4 gene locus. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(1):309-314.
30. Drew A.E., Derbez A.E., et al. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse 2000, 38(1):10-16.
31. Dunger D.B., Ong K.K., et al. Association of the INS VNTR with size at birth. ALSPAC study team. Avon longitudinal study of pregnancy and childhood. Nat. Genet. 1998, 19(1):98-100.
32. Fergusson D.M., Boden J.M., et al. Moderating role of the MAOA genotype in antisocial behaviour. Br. J. Psychiatry 2012, 200(2):116-123.
33. Fergusson D.M., Boden J.M., et al. MAOA, abuse exposure and antisocial behaviour: 30-year longitudinal study. Br. J. Psychiatry 2011, 198(6):457-463.
34. Ferk P., Perme M.P., et al. Insulin gene polymorphism in women with polycystic ovary syndrome. J. Int. Med. Res. 2008, 36(6):1180-1187.
35. Fondon J.W., Hammock E.A., et al. Simple sequence repeats: genetic modulators of brain function and behavior. Trends Neurosci. 2008, 31(7):328-334.
36. Frazzetto G., Di Lorenzo G., et al. Early trauma and increased risk for physical aggression during adulthood: the moderating role of MAOA genotype. PLoS One 2007, 2(5):e486.
37. Fridley B.L., Biernacka J.M. Gene set analysis of SNP data: benefits, challenges, and future directions. Eur. J. Hum. Genet. 2011, 19(8):837-843.
38. Fuke S., Sasagawa N., et al. Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 3' non-coding polymorphic region of the human dopamine transporter (DAT1) gene. J. Biochem. 2005, 137(2):205-216.
39. Fuke S., Suo S., et al. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 2001, 1(2):152-156.
40. Greenwood T.A., Kelsoe J.R. Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 2003, 82(5):511-520.
41. Guja C., Guja L., et al. Strong association of insulin gene INS-VNTR polymorphisms with type 1 diabetes in the Romanian population. Rom. J. Intern. Med. 2004, 42(2):313-323.
42. Guo G., Ou X.M., et al. The VNTR 2 repeat in MAOA and delinquent behavior in adolescence and young adulthood: associations and MAOA promoter activity. Eur. J. Hum. Genet. 2008, 16(5):626-634.
43. Haberstick B.C., Lessem J.M., et al. Monoamine oxidase A (MAOA) and antisocial behaviors in the presence of childhood and adolescent maltreatment. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 135B(1):59-64.
44. Haddley K., Bubb V.J., et al. Behavioural genetics of the serotonin transporter. Curr. Top. Behav. Neurosci. 2012, 12:503-535.
45. Handsaker R.E., Korn J.M., et al. Discovery and genotyping of genome structural polymorphism by sequencing on a population scale. Nat. Genet. 2011, 43(3):269-276.
46. Hannan A.J. Tandem repeat polymorphisms: modulators of disease susceptibility and candidates for 'missing heritability'. Trends Genet. 2010, 26(2):59-65.
47. Hansen S.K., Gjesing A.P., et al. Large-scale studies of the HphI insulin gene variable-number-of-tandem-repeats polymorphism in relation to type 2 diabetes mellitus and insulin release. Diabetologia 2004, 47(6):1079-1087.
48. He D., Hormozdiari F., et al. Efficient algorithms for tandem copy number variation reconstruction in repeat-rich regions. Bioinformatics 2011, 27(11):1513-1520.
49. Heils A., Teufel A., et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 1996, 66(6):2621-2624.
50. Heude B., Dubois S., et al. VNTR polymorphism of the insulin gene and childhood overweight in a general population. Obes. Res. 2004, 12(3):499-504.
51. Heude B., Petry C.J., et al. The insulin gene variable number of tandem repeat: associations and interactions with childhood body fat mass and insulin secretion in normal children. J. Clin. Endocrinol. Metab. 2006, 91(7):2770-2775.
52. Hindorff L.A., Sethupathy P., et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(23):9362-9367.
53. Hu X.Z., Lipsky R.H., et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 2006, 78(5):815-826.
54. Huang Y.Y., Cate S.P., et al. An association between a functional polymorphism in the monoamine oxidase a gene promoter, impulsive traits and early abuse experiences. Neuropsychopharmacology 2004, 29(8):1498-1505.
55. Huizinga D., Haberstick B.C., et al. Childhood maltreatment, subsequent antisocial behavior, and the role of monoamine oxidase A genotype. Biol. Psychiatry 2006, 60(7):677-683.
56. Huxtable S.J., Saker P.J., et al. Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles. Diabetes 2000, 49(1):126-130.
57. Jovanovic V., Guan H.C., et al. Comparative pharmacological and functional analysis of the human dopamine D4.2 and D4.10 receptor variants. Pharmacogenetics 1999, 9(5):561-568.
58. Kanno K., Ishiura S. Differential effects of the HESR/HEY transcription factor family on dopamine transporter reporter gene expression via variable number of tandem repeats. J. Neurosci. Res. 2011, 89(4):562-575.
59. Karaoz E., Demircan P.C., et al. Human dental pulp stem cells demonstrate better neural and epithelial stem cell properties than bone marrow-derived mesenchymal stem cells. Histochem. Cell Biol. 2011, 136(4):455-473.
60. Kazmi M.A., Snyder L.A., et al. Selective reconstitution of human D4 dopamine receptor variants with Gi alpha subtypes. Biochemistry 2000, 39(13):3734-3744.
61. Kennedy G.C., German M.S., et al. The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. Nat. Genet. 1995, 9(3):293-298.
62. Kraft P., Hunter D. Integrating epidemiology and genetic association: the challenge of gene-environment interaction. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2005, 360(1460):1609-1616.
63. Krause K.H., Dresel S.H., et al. Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Int. J. Neuropsychopharmacol. 2002, 5(2):111-113.
64. Ku C.S., Loy E.Y., et al. The discovery of human genetic variations and their use as disease markers: past, present and future. J. Hum. Genet. 2010, 55(7):403-415.
65. LaHoste G.J., Swanson J.M., et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry 1996, 1(2):121-124.
66. Lakhani K., Prelevic G.M., et al. Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors. J. Obstet. Gynaecol. 2004, 24(6):613-621.
67. Lander E.S. The new genomics: global views of biology. Science 1996, 274(5287):536-539.
68. Lander E.S., Linton L.M., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409(6822):860-921.
69. Li C., Han J., et al. Identifying disease related sub-pathways for analysis of genome-wide association studies. Gene 2012, 503(1):101-109.
70. Lichter J.B., Barr C.L., et al. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum. Mol. Genet. 1993, 2(6):767-773.
71. Licinio J. Gene-environment interactions in molecular psychiatry. Mol. Psychiatry 2002, 7(2):123-124.
72. Lim L.C., Powell J., et al. Evidence for a genetic association between alleles of monoamine oxidase A gene and bipolar affective disorder. Am. J. Med. Genet. 1995, 60(4):325-331.
73. Lucassen A.M., Screaton G.R., et al. Regulation of insulin gene expression by the IDDM associated, insulin locus haplotype. Hum. Mol. Genet. 1995, 4(4):501-506.
74. Maas J.A., Mook-Kanamori D.O., et al. Insulin VNTR and IGF-1 promoter region polymorphisms are not associated with body composition in early childhood: the generation R study. Horm. Res. Paediatr. 2010, 73(2):120-127.
75. Magnotti M., Futterweit W. Obesity and the polycystic ovary syndrome. Med. Clin. North Am. 2007, 91(6):1151-1168. (ix-x).
76. Maher B. Personal genomes: the case of the missing heritability. Nature 2008, 456(7218):18-21.
77. Manolio T.A., Collins F.S., et al. Finding the missing heritability of complex diseases. Nature 2009, 461(7265):747-753.
78. Marian A.J. Elements of 'missing heritability'. Curr. Opin. Cardiol. 2012, 27(3):197-201.
79. Mayfield R.D., Maiya R., et al. Ethanol potentiates the function of the human dopamine transporter expressed in Xenopus oocytes. J. Neurochem. 2001, 79(5):1070-1079.
80. Meigs J.B., Dupuis J., et al. The insulin gene variable number tandem repeat and risk of type 2 diabetes in a population-based sample of families and unrelated men and women. J. Clin. Endocrinol. Metab. 2005, 90(2):1137-1143.
81. Michelhaugh S.K., Fiskerstrand C., et al. The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. J. Neurochem. 2001, 79(5):1033-1038.
82. Mignone F., Gissi C., et al. Untranslated regions of mRNAs. Genome Biol. 2002, 3(3). (REVIEWS0004).
83. Mill J., Asherson P., et al. Expression of the dopamine transporter gene is regulated by the 3' UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am. J. Med. Genet. 2002, 114(8):975-979.
84. Mill J., Asherson P., et al. Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet. 2005, 6:3.
85. Miller G.M., Madras B.K. Polymorphisms in the 3'-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol. Psychiatry 2002, 7(1):44-55.
86. Moffitt T.E. The new look of behavioral genetics in developmental psychopathology: gene-environment interplay in antisocial behaviors. Psychol. Bull. 2005, 131(4):533-554.
87. Mortensen O.V., Thomassen M., et al. Functional analysis of a novel human serotonin transporter gene promoter in immortalized raphe cells. Brain Res. Mol. Brain Res. 1999, 68(1-2):141-148.
88. Nakamura M., Ueno S., et al. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol. Psychiatry 2000, 5(1):32-38.
89. Nourbakhsh N., Soleimani M., et al. Induced in vitro differentiation of neural-like cells from human exfoliated deciduous teeth-derived stem cells. Int. J. Dev. Biol. 2011, 55(2):189-195.
90. Oldenhof J., Vickery R., et al. SH3 binding domains in the dopamine D4 receptor. Biochemistry 1998, 37(45):15726-15736.
91. Ong K.K., Dunger D.B. Birth weight, infant growth and insulin resistance. Eur. J. Endocrinol. 2004, 151(Suppl. 3):U131-U139.
92. Ong K.K., Phillips D.I., et al. The insulin gene VNTR, type 2 diabetes and birth weight. Nat. Genet. 1999, 21(3):262-263.
93. Osada H., Seki K., et al. Genetic variations within the insulin gene region are associated with accelerated fetal growth. Tohoku J. Exp. Med. 2007, 212(1):27-34.
94. Paquette J., Varin D.S., et al. Risk of autoimmune diabetes in APECED: association with short alleles of the 5' insulin VNTR. Genes Immun. 2010, 11(7):590-597.
95. Pasquali R., Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann. N. Y. Acad. Sci. 2006, 1092:158-174.
96. Pinsonneault J.K., Han D.D., et al. Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology 2011, 36(8):1644-1655.
97. Pinsonneault J.K., Papp A.C., et al. Allelic mRNA expression of X-linked monoamine oxidase a (MAOA) in human brain: dissection of epigenetic and genetic factors. Hum. Mol. Genet. 2006, 15(17):2636-2649.
98. Plomin R. Child development and molecular genetics: 14years later. Child Dev. 2013, 84(1):104-120.
99. Preece P., Cairns N.J. Quantifying mRNA in postmortem human brain: influence of gender, age at death, postmortem interval, brain pH, agonal state and inter-lobe mRNA variance. Brain Res. Mol. Brain Res. 2003, 118(1-2):60-71.
100. Prom-Wormley E.C., Eaves L.J., et al. Monoamine oxidase A and childhood adversity as risk factors for conduct disorder in females. Psychol. Med. 2009, 39(4):579-590.
101. Rani R., Sood A., et al. Molecular basis of predisposition to develop type 1 diabetes mellitus in North Indians. Tissue Antigens 2004, 64(2):145-155.
102. Richard-Miceli C., Criswell L.A. Emerging patterns of genetic overlap across autoimmune disorders. Genome Med. 2012, 4(1):6.
103. Risch N., Merikangas K. The future of genetic studies of complex human diseases. Science 1996, 273(5281):1516-1517.
104. Sabol S.Z., Hu S., et al. A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet. 1998, 103(3):273-279.
105. Samochowiec J., Lesch K.P., et al. Association of a regulatory polymorphism in the promoter region of the monoamine oxidase A gene with antisocial alcoholism. Psychiatry Res. 1999, 86(1):67-72.
106. Schlotterer C. The evolution of molecular markers-just a matter of fashion?. Nat. Rev. Genet. 2004, 5(1):63-69.
107. Schoots O., Van Tol H.H. The human dopamine D4 receptor repeat sequences modulate expression. Pharmacogenomics J. 2003, 3(6):343-348.
108. Seaman M.I., Fisher J.B., et al. Tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4). Am. J. Med. Genet. 1999, 88(6):705-709.
109. Sherry S.T., Ward M.H., et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001, 29(1):308-311.
110. Shumay E., Fowler J.S. Identification and characterization of putative methylation targets in the MAOA locus using bioinformatic approaches. Epigenetics 2010, 5(4):325-342.
111. Simpson J., Vetuz G., et al. The DRD4 receptor Exon 3 VNTR and 5' SNP variants and mRNA expression in human post-mortem brain tissue. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B(6):1228-1233.
112. Tabor H.K., Risch N.J., et al. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat. Rev. Genet. 2002, 3(5):391-397.
113. Thanseem I., Anitha A., et al. Elevated transcription factor specificity protein 1 in autistic brains alters the expression of autism candidate genes. Biol. Psychiatry 2012, 71(5):410-418.
114. Tomita H., Vawter M.P., et al. Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol. Psychiatry 2004, 55(4):346-352.
115. Treangen T.J., Salzberg S.L. Repetitive DNA and next-generation sequencing: computational challenges and solutions. Nat. Rev. Genet. 2012, 13(1):36-46.
116. Usdin K. The biological effects of simple tandem repeats: lessons from the repeat expansion diseases. Genome Res. 2008, 18(7):1011-1019.
117. Vafiadis P., Bennett S.T., et al. Imprinted and genotype-specific expression of genes at the IDDM2 locus in pancreas and leucocytes. J. Autoimmun. 1996, 9(3):397-403.
118. Vafiadis P., Bennett S.T., et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat. Genet. 1997, 15(3):289-292.
119. Van Craenenbroeck K., Clark S.D., et al. Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis. J. Biol. Chem. 2005, 280(19):19350-19357.
120. Van Tol H.H., Bunzow J.R., et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991, 350(6319):610-614.
121. VanNess S.H., Owens M.J., et al. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 2005, 6:55.
122. Vinkhuyzen A.A., Dumenil T., et al. Identification of tag haplotypes for 5HTTLPR for different genome-wide SNP platforms. Mol. Psychiatry 2011, 16(11):1073-1075.
123. Visscher P.M., Brown M.A., et al. Five years of GWAS discovery. Am. J. Hum. Genet. 2012, 90(1):7-24.
124. Wakschlag L.S., Kistner E.O., et al. Interaction of prenatal exposure to cigarettes and MAOA genotype in pathways to youth antisocial behavior. Mol. Psychiatry 2010, 15(9):928-937.
125. Walter M., Albert E., et al. IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of type 1 diabetes and associated autoimmunity. Diabetologia 2003, 46(5):712-720.
126. Wang D., Sun X., et al. CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers. Drug Metab. Dispos. 2012, 40(5):884-891.
127. Wang E., Ding Y.C., et al. The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus. Am. J. Hum. Genet. 2004, 74(5):931-944.
128. Wang S., Wang M., et al. A novel variable number of tandem repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5 is a risk factor for human bladder cancer. Mutat. Res. 2008, 638(1-2):26-36.
129. Waterworth D.M., Bennett S.T., et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997, 349(9057):986-990.
130. Wu Y.H., Fischer D.F., et al. A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer's disease patients. Brain Res. 2007, 1167:13-19.
131. Xie C., Tammi M.T. CNV-seq, a new method to detect copy number variation using high-throughput sequencing. BMC Bioinforma. 2009, 10:80.
132. Yaspan B.L., Veatch O.J. Strategies for pathway analysis from GWAS data. Curr. Protoc. Hum. Genet. 2011, (Chapter 1: Unit1 20).
133. Yun J.H., Gu B.H., et al. Association between INS-VNTR polymorphism and polycystic ovary syndrome in a Korean population. Gynecol. Endocrinol. 2012, 28(7):525-528.
134. Zarrin A.A., Malkin L., et al. Comparison of CMV, RSV, SV40 viral and Vlambda1 cellular promoters in B and T lymphoid and non-lymphoid cell lines. Biochim. Biophys. Acta 1999, 1446(1-2):135-139.
135. Zuk O., Hechter E., et al. The mystery of missing heritability: genetic interactions create phantom heritability. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(4):1193-1198.
136. Zukic B., Radmilovic M., et al. Functional analysis of the role of the TPMT gene promoter VNTR polymorphism in TPMT gene transcription. Pharmacogenomics 2010, 11(4):547-557.